DPPIV (CD26) as a novel stem cell marker in Ph plus chronic myeloid leukaemia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F14%3A00078413" target="_blank" >RIV/00216224:14110/14:00078413 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/65269705:_____/14:00061794

Výsledek na webu

<a href="http://dx.doi.org/10.1111/eci.12368" target="_blank" >http://dx.doi.org/10.1111/eci.12368</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/eci.12368" target="_blank" >10.1111/eci.12368</a>

Jazyk výsledku

angličtina

Název v původním jazyce

DPPIV (CD26) as a novel stem cell marker in Ph plus chronic myeloid leukaemia

Popis výsledku v původním jazyce

The concept of leukaemic stem cells (LSCs) has been developed to explain the complex cellular hierarchy and biology of leukaemias and to screen for pivotal targets that can be employed to improve drug therapies through LSC eradication in these patients.Some of the newly discovered LSC markers seem to be expressed in a disease-specific manner and may thus serve as major research tools and diagnostic parameters. A useful LSC marker in chronic myeloid leukaemia (CML) appears to be CD26, also known as dipeptidylpeptidase IV. Expression of CD26 is largely restricted to CD34(+)/CD38(-) LSCs in BCR/ABL1(+) CML, but is not found on LSCs in other myeloid or lymphoid neoplasms, with the exception of lymphoid blast crisis of CML, BCR/ABL1(p210)+ acute lymphoblastic leukaemia, and a very few cases of acute myeloid leukaemia. Moreover, CD26 usually is not expressed on normal bone marrow (BM) stem cells.

Název v anglickém jazyce

DPPIV (CD26) as a novel stem cell marker in Ph plus chronic myeloid leukaemia

Popis výsledku anglicky

The concept of leukaemic stem cells (LSCs) has been developed to explain the complex cellular hierarchy and biology of leukaemias and to screen for pivotal targets that can be employed to improve drug therapies through LSC eradication in these patients.Some of the newly discovered LSC markers seem to be expressed in a disease-specific manner and may thus serve as major research tools and diagnostic parameters. A useful LSC marker in chronic myeloid leukaemia (CML) appears to be CD26, also known as dipeptidylpeptidase IV. Expression of CD26 is largely restricted to CD34(+)/CD38(-) LSCs in BCR/ABL1(+) CML, but is not found on LSCs in other myeloid or lymphoid neoplasms, with the exception of lymphoid blast crisis of CML, BCR/ABL1(p210)+ acute lymphoblastic leukaemia, and a very few cases of acute myeloid leukaemia. Moreover, CD26 usually is not expressed on normal bone marrow (BM) stem cells.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Clinical Investigation

ISSN

0014-2972

e-ISSN

—

Svazek periodika

44

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

1239-1245

Kód UT WoS článku

000345759100012

EID výsledku v databázi Scopus

—